64 results
Page 2 of 4
424B5
hzh5a9hbwf2 4zv
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-1.1
gb5cbe
16 Jul 21
Entry into a Material Definitive Agreement
4:14pm
424B5
7yvtrl
16 Jul 21
Prospectus supplement for primary offering
4:07pm
8-K
EX-10.1
sdvnlakah5dpb 2sia
13 Nov 20
Termination of a Material Definitive Agreement
4:02pm
8-K
EX-1.1
ql8dlofdqqfqgaq3an
26 Jun 20
Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock
4:31pm
424B5
8nelquf57cr 1m57wz
25 Jun 20
Prospectus supplement for primary offering
4:01pm
424B5
p1tjo
23 Jun 20
Prospectus supplement for primary offering
4:06pm
8-K
EX-99.1
yn4rdypptqej2c
6 Jan 20
Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome
5:01pm
8-K
EX-1.1
urd94
25 Oct 19
Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock
4:03pm
424B5
ruot6035x jo4gp
25 Oct 19
Prospectus supplement for primary offering
12:00am
424B5
he1 8ngvtegaw2iw
22 Oct 19
Prospectus supplement for primary offering
4:24pm
S-3
caht 4u4x6mf
11 Jun 19
Shelf registration
5:05pm
424B3
0kroryra81b8uu gv2
12 Apr 19
Prospectus supplement
4:41pm